Argenx Se Bdr (A1RG34) Stock Price & News

Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia

About Argenx Se Bdr

CEO-

Employees1.86 ሺ

Founded25 ኤፕሪ 2008

Headquarters-

SectorHealth Care

IndustryBiotechnology

Websiteargenx.com

All values in USD	ዲሴም 2025	ማርች 2026	ጁን 2026	ሴፕቴ 2026
Revenue	1.31 ቢ	1.31 ቢ	1.54 ቢ	1.75 ቢ
Cost of goods sold	521.40 ሚ	564.00 ሚ	631.00 ሚ	668.00 ሚ
Cost of revenue	521.40 ሚ	564.00 ሚ	631.00 ሚ	668.00 ሚ
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	429.62 ሚ	355.00 ሚ	417.00 ሚ	448.00 ሚ
Operating expense	429.62 ሚ	355.00 ሚ	417.00 ሚ	448.00 ሚ
Total operating expenses	951.02 ሚ	919.00 ሚ	1.05 ቢ	1.12 ቢ
Operating income	359.56 ሚ	394.00 ሚ	493.00 ሚ	635.00 ሚ
Other non operating income	-907.00 ሺ	-	-1.00 ሚ	1.00 ሚ
EBT including unusual items	403.29 ሚ	426.00 ሚ	531.00 ሚ	538.00 ሚ
EBT excluding unusual items	391.71 ሚ	426.00 ሚ	531.00 ሚ	688.00 ሚ
Income tax expense	-129.66 ሚ	60.00 ሚ	59.00 ሚ	32.00 ሚ
Effective tax rate	-32.15%	14.08%	11.11%	5.95%
Other operating expenses	-	-	-	-
Net income	532.95 ሚ	366.00 ሚ	472.00 ሚ	506.00 ሚ
Net profit margin	40.67%	27.88%	30.63%	28.90%
Earnings per share	8.02	5.52	7.32	7.80
Interest and investment income	44.95 ሚ	44.00 ሚ	48.00 ሚ	45.00 ሚ
Interest expense	-	-1.00 ሚ	-1.00 ሚ	-1.00 ሚ
Net interest expenses	44.95 ሚ	43.00 ሚ	47.00 ሚ	44.00 ሚ
Depreciation and amortization charges	-	-	-	-
EBITDA	361.38 ሚ	395.82 ሚ	501.50 ሚ	636.82 ሚ
Gain or loss from assets sale	-	-	-	-

Ask anything